Autoimmune diseases

Ultra-low dose rituximab shows promise for pemphigus

Off-label use of low dose  rituximab may be a valuable option for management of  pemphigus, experience at a Victorian hospital suggests. Clinicians at the Department of Dermatology, Royal Melbourne Hospital have described how some patients have achieved control of pemphigus within a month after receiving ultra-low doses of rituximab. In their report, published in the ...

Already a member?

Login to keep reading.

© 2021 the limbic